Related references
Note: Only part of the references are listed.The FDA as a Public Health Agency
Margaret A. Hamburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
HIV clinical trial design for antiretroviral development: moving forward
Kirk M. Chan-Tack et al.
AIDS (2008)
A new approach for 'deep salvage' trials in advanced HIV infection
Michael M. Lederman et al.
AIDS (2007)
Biology of CCR5 and its role in HIV infection and treatment
Michael M. Lederman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B. Hicks et al.
LANCET (2006)
Antiretroviral therapies for treatment-experienced patients: current status and research challenges
K Struble et al.
AIDS (2005)
What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection
PC Tien et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2004)
Monitoring of long-term toxicities of HIV treatments: an international perspective
G Bisson et al.
AIDS (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
